These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20425405)

  • 1. Antilymphoma therapy with a Bcl-6 inhibitor.
    McLaughlin P
    Curr Hematol Malig Rep; 2009 Oct; 4(4):183-4. PubMed ID: 20425405
    [No Abstract]   [Full Text] [Related]  

  • 2. THE ANTICOAGULANT AND ANTILYMPHOMA PROPERTIES OF ARSENIC AZOPROTEINS : I. ANTICOAGULANT EFFECTS OF ARSENIC AZOPROTEINS IN VIVO AND IN VITRO: COMPARISON OF ARSENICALS AS ANTICOAGULANTS AND AS ANTILYMPHOMA AGENTS: MOLECULAR STRUCTURE IN RELATION TO ANTICOAGULANT AND ANTILYMPHOMA PROPERTIES.
    Broome JD; Kidd JG
    J Exp Med; 1964 Sep; 120(3):449-66. PubMed ID: 19867291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense therapy of hematologic malignancies.
    Cotter FE
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):9-14. PubMed ID: 10530711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance.
    BROOME JD
    J Exp Med; 1963 Jul; 118(1):99-120. PubMed ID: 14015821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat.
    Rossini A; Zunino F; Ruggiero G; De Cesare M; Cominetti D; Tortoreto M; Lanzi C; Cassinelli G; Zappasodi R; Tripodo C; Gulino A; Zaffaroni N; Di Nicola M
    Hematol Oncol; 2018 Feb; 36(1):360-362. PubMed ID: 28730742
    [No Abstract]   [Full Text] [Related]  

  • 6. [Mantle Cell Lymphoma -  Cutting edge Dia-gnostics and Treatment Approaches].
    Klener P; Trněný M
    Klin Onkol; 2015; 28 Suppl 3():3S80-6. PubMed ID: 26489506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors.
    Mensah AA; Spriano F; Sartori G; Priebe V; Cascione L; Gaudio E; Tarantelli C; Civanelli E; Aresu L; Rinaldi A; Damia G; Lovati E; Zucca E; Stathis A; Pietra C; Bertoni F
    Blood Adv; 2021 May; 5(10):2467-2480. PubMed ID: 33999145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells.
    West J; Perkins J; Hok S; Balhorn R; Lightstone FC; Cosman M; DeNardo SJ; DeNardo GL
    Cancer Biother Radiopharm; 2006 Dec; 21(6):645-54. PubMed ID: 17257080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The JAK2 inhibitor TG101209 exhibits anti-tumor and chemotherapeutic sensitizing effects on Burkitt lymphoma cells by inhibiting the JAK2/STAT3/c-MYB signaling axis.
    Zhang Y; Li J; Zhong H; Xiao X; Wang Z; Cheng Z; Hu C; Zhang G; Liu S
    Cell Death Discov; 2021 Sep; 7(1):268. PubMed ID: 34588425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.
    Rutherford SC; Stewart EN; Chen Z; Chadburn A; Wehrli NE; van Besien K; Martin P; Furman RR; Leonard JP; Cerchietti L
    Leuk Lymphoma; 2018 Jan; 59(1):256-258. PubMed ID: 28573908
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy.
    Little RF; Yarchoan R; Wilson WH
    Curr Opin Oncol; 2000 Sep; 12(5):438-44. PubMed ID: 10975551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.
    Cerchietti LC; Yang SN; Shaknovich R; Hatzi K; Polo JM; Chadburn A; Dowdy SF; Melnick A
    Blood; 2009 Apr; 113(15):3397-405. PubMed ID: 18927431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies.
    DeNardo GL; Tobin E; Chan K; Bradt BM; DeNardo SJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7075s-7079s. PubMed ID: 16203805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
    Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
    Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
    Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
    Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.
    Farsaci B; Sabzevari H; Higgins JP; Di Bari MG; Takai S; Schlom J; Hodge JW
    Int J Cancer; 2010 Oct; 127(7):1603-13. PubMed ID: 20091862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.
    Ci W; Polo JM; Melnick A
    Curr Opin Hematol; 2008 Jul; 15(4):381-90. PubMed ID: 18536578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxycodone inhibits myocardial cell apoptosis after myocardial ischemia-reperfusion injury in rats via RhoA/ROCK1 signaling pathway.
    Xie Y; Ge CL; Zhang ZY; Fei GX
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6371-6379. PubMed ID: 32572934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of propofol on myocardial ischemia/reperfusion injury in rats through JAK/STAT signaling pathway.
    Chen X; Wang Y; Xiao ZY; Hou DN; Li DB; Zhang XP
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6330-6338. PubMed ID: 31364140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL-2 levels do not predict azathioprine treatment response in inflammatory bowel disease, but inhibition induces lymphocyte apoptosis and ameliorates colitis in mice.
    Weder B; Mozaffari M; Biedermann L; Mamie C; Moncsek A; Wang L; Clarke SH; Rogler G; McRae BL; Graff CL; Ruiz PA; Hausmann M
    Clin Exp Immunol; 2018 Sep; 193(3):346-360. PubMed ID: 29745420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.